• Explore /
  • Poster
  • / Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q).

Clinical benefit among lenalidomide (LEN)-treated patients (pts) with RBC transfusion-dependent (RBC-TD) low-/int-1-risk myelodysplastic syndromes (MDS) without del(5q).

Abstract Poster

Authors

null

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center, Houston, TX

Guillermo Garcia-Manero , Antonio Medina Almeida , Pierre Fenaux , Norbert Gattermann , Aristoteles Giagounidis , Stuart Goldberg , Keiya Ozawa , Jerry Weaver , Mary M. Sugrue , Valeria Santini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT01029262

Citation

J Clin Oncol 34, 2016 (suppl; abstr 7014)

DOI

10.1200/JCO.2016.34.15_suppl.7014

Abstract #

7014

Poster Bd #

6

Abstract Disclosures

Similar Posters

First Author: Pierre Fenaux

First Author: Uwe Platzbecker

Poster

2021 ASCO Annual Meeting

Choosing unwisely: Low-value care in older adults with a diagnosis of myelodysplastic syndrome.

Choosing unwisely: Low-value care in older adults with a diagnosis of myelodysplastic syndrome.

First Author: Sudipto Mukherjee

First Author: Antonio Medina Almeida